The Vital Role of Screening in Early Detection and Prevention

Screening is an indispensable tool in safeguarding public health, pinpointing individuals who might be affected by specific conditions or illnesses even before symptoms surface. Its significance extends across various domains within communities, facilitating early detection of diseases, enhancing treatment effectiveness, and curbing the transmission of illnesses by identifying carriers and risk factors. Additionally, it fosters health equity by ensuring universal access irrespective of socioeconomic status while also curbing expenses by averting the necessity for costly treatments down the line.

Additionally, screening programs provide valuable data for public health planning, informing policies and resource allocation to address specific community health needs. Furthermore, screening raises awareness and educates communities about health issues, fostering proactive approaches to disease prevention and management.

It is reported that more than 55% of cancers are prevented with modifying the factors we have control over, such as smoking, alcohol use, high body-mass index, and a diet high in processed and red meat, whereas the remaining cases are related to non-modifiable risk factors including genetic factors, personal history of polyps or adenoma, or family history of colorectal cancer.

When looking at colorectal cancer screening, BACH Clinical Director Dr. Gemma Jamena highlights its critical importance: "By detecting precancerous polyps early, these screenings allow for their removal before they develop into cancer, significantly reducing the risk of colorectal cancer."

She emphasizes the significance of early detection, stressing that "when colorectal cancer is detected in its early stages, specifically during the first stage, the five-year survival rate can be as high as 90%."

To motivate proactive behavior, BACH hosts an ongoing raffle for all patients participating in colorectal screening efforts.

To ensure equitable access to healthcare for all, BACH provides fecal immunochemical test (FIT) and Cologuard kits to uninsured as well as insured patients. These noninvasive at-home colon cancer screening tests require no preparation, overcoming transportation barriers and ensuring comprehensive care.